linjc16/ctgov huggingface dataset:
Non-Specific Chronic Back Pain; Insight From Spatial Aspects of Lumbar Spinal Muscle Activation

Study Overview
=================
Brief Summary
-----------------
There is evidence for altered muscle activity patterns in individuals with non-specific chronic back pain (NSCBP). It is unknown why these alterations in activation pattern occur and how they may be linked to pain experience and to the development of CNSBP. The main objective of this study is to investigate the spatial aspects of muscle activation in relation to fatigue/endurance and CNSBP. A novel approach, utilizing a new multi-channel surface-EMG (MCsEMG) technique will be applied in this project to get insight in fundamental mechanisms related to motor control and fatigue/endurance. In this project data from healthy persons and from patients with NSCBP will be collected and analyzed. NSCBP patients will be compared to healthy persons. To minimize heterogeneity between groups the subject's age range will be from 30 - 50 years. The investigators main hypothesis is that motor control mechanisms of the lumbar muscles are disturbed in NSCBP patients compared to normals, explaining the reduced tolerance for static postures. There has been little investigation of the lumbar musculature with MCsEMG recordings. The lumbar musculature has a complex organization; many, relatively small muscles, in a restricted area. Utilizing two HDsEMG grids with 252 Ag/AgCl contacts will be the superior non-invasive method to investigate motor control mechanisms in this region, and further the investigators understanding of neuromuscular adaptations related to NSCBP. The project may demonstrate changes that will lead us to new insight and new strategies for the treatment of back pain.

Official Title
-----------------
NON-SPECIFIC CHRONIC BACK PAIN; INSIGHT FROM SPATIAL ASPECTS OF LUMBAR SPINAL MUSCLE ACTIVATION

Conditions
-----------------
Low Back Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients diagnosed with chronic NSCBP >3 months duration healthy controls no back pain. Exclusively exclusion criteria for this group will be back pain in the previous year or back pain lasting longer than one week in previous 3 years. Exclusion Criteria: anamnesis of medical or drug abuse surgery on the musculoskeletal system of the trunk known congenital malformation of the spine or scoliosis body mass index >27 kg/m2 systemic-neurological-degenerative disease history of stroke psychiatric disorder pregnancy and abnormal blood pressure.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Autoantibodies in Patients With Type 1 Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
Evaluate the autoantibodies, such as glutamic acid decarboxylase (GAD65), tyrosine phosphatase (IA-2 or ICA125), islet autoantibodies (IAA) and other associated autoimmune autoantibodies: microsomal antibodies, thyroglobulin antibodies, gastric parietal cell antibodies in patients with type 1 DM.

Detailed Description
-----------------
Type 1 diabetes mellitus (DM) is a common disease in pediatric endocrine clinic and epidemiological studies showed the racial variation in the incidence, with the highest of 35 cases per 100000 in Finland. The incidence of type 1 DM in Taiwan is reported to be 1.5 per 100000 for the population less than 30 years old. While the diagnosis is made, the residual islet cell function is only about 20% of normal population. Therefore, the principle therapy in these patients is insulin therapy lifelong. The pathogenesis of type 1 diabetes mellitus is multifactorial and controversial, involving the genetic and environmental factors. Type 1 DM is an autoimmune disease, which is T cell mediated islet cell destruction. Ninety percent of patients with type 1 DM express at least one of the autoantibodies to the islet. Antibodies to glutamic acid decarboxylase 65 (GAD65) were observed in 60-80% of such patients, which were considered the most important autoantigens. The autoantibodies disappeared successively after diagnosis and decreased in concentrations over time, but titers of antibodies to GAD65 had been observed fluctuated in patients with type 1 DM. The prevalence of GAD antibodies, insulin autoantibodies, IA-2 (tyrosine phosphatase) were reported as 45-67%, 23-67% and 49%, respectively in Taiwan. Other associated autoimmune disease, such as autoimmune thyroiditis were reported as 13-24%. Such differences may be caused by the enrolling criteria and different age population. Therefore, we want to elucidate the role of autoantibodies in the pathogenesis of type 1 DM.

Conditions
-----------------
Type 1 Diabetes

Intervention / Treatment
-----------------
* Procedure: blood drawing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pediatric patients with type 1 diabetes

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: blood drawing|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Cerebral Blood Circulation in Patients With Posterior Fossa Brain Tumor

Study Overview
=================
Brief Summary
-----------------
The normal cerebral blood flow is guided by factors such as cerebral autoregulation (CA) and carbon dioxide reactivity (CO2R). Authors have demonstrated that CA and CO2R may be impaired in presence of intracranial tumors.Most studies pertaining to assessment of CA and CO2R in patients with brain tumors is limited to supratentorial tumors. Due to their anatomic location, posterior fossa tumors result in obstruction of ventricular outflow, produce hydrocephalus and features of raise intracranial pressure (ICP). It is possible that lesions in the posterior fossa may affect CA and CO2R. It should also be noted that posterior fossa surgeries are carried out in positions such as prone, lateral and sitting. Altered surgical positions themselves affect systemic hemodynamics which may influence cerebral blood flow; with presence of anesthetics further compromising the blood flow to the brain. Understanding the homeostatic mechanisms of CA and CO2R may help in deciding proper positioning of patients and maintenance of intraoperative hemodynamic. The aim of this observational study was to evaluate CA and CO2R in patients with posterior fossa tumor prior to surgical decompression of the lesion.

Official Title
-----------------
Cerebral Autoregulation and Carbon Dioxide Reactivity in Patients With Posterior Fossa Tumor

Conditions
-----------------
Brain Tumor

Intervention / Treatment
-----------------
* Other: Monitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with posterior fossa tumor Scheduled for elective surgery History of recent ventriculoperitoneal shunt (within 24 hours) Exclusion Criteria: previous craniotomy patients on ventilatory support history of cerebrovascular accident syncope or carotid artery disease anemia polycythemia patients on vasoactive medications those suffering from medical conditions such as diabetes mellitus and hypertension.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Posterior fossa tumor<br>Patients with posterior fossa tumor scheduled for elective surgery will be enrolled in the study. | Other: Monitoring<br>* Transcranial Doppler will be used to assess the cerebral autoregulation and carbon dioxide reactivity of patients with posterior fossa tumor<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Posterior fossa brain tumor, Cerebral blood flow, Cerebral autoregulation, Carbon dioxide reactivity, Transcranial Doppler
Signal Analysis for Neurocritical Patients

Study Overview
=================
Brief Summary
-----------------
The project uses big data analysis techniques such as wavelet transform and deep learning to analyze physiological signals from neurocritical patients and build a model to evaluate intracranial condition and to predict neurological outcome. By identification of correlations among these parameters and their trends, we may achieve early detection of anomalies and enhance the ability in judgement of current neurological condition and prediction of prognosis. By continuous input of the past and contemporary data in the ICU, the model will be modified repeatedly and its accuracy improves as the model grows. The model can be used to recognize abnormalities earlier and provide a warning system. Clinicians taking care of neurocritical patients can adjust their treatment policy and evaluate the outcome according to such system.

Official Title
-----------------
Analysis of Physiological Signals From Neurocritical Patients in Intensive Care Units Using Wavelet Transform and Deep Learning

Conditions
-----------------
Brain Injuries, Acute

Intervention / Treatment
-----------------
* Device: intracranial pressure monitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age equal to or older than 20 years Neurocritical patients admitted to intensive care unit (ICU), including but not limited to traumatic brain injury, hemorrhagic stroke, ischemic stroke, brain infection, brain tumor and acute hydrocephalus. Patients who have undergone cranial surgery and had intracranial pressure monitor inserted or external ventricular drainage. The central monitor of ICU is able to collect the data continuously Exclusion Criteria: Age younger than 20 years. Continuous monitoring of intracranial pressure is not feasible.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neurocritical patients<br>Patients with brain injury from trauma, ischemic stroke, hemorrhage stroke (intracerebral hemorrhage, subarachnoid hemorrhage), brain tumor with increased intracranial pressure, brain infection, hydrocephalus, among others. | Device: intracranial pressure monitoring<br>* The patients may have either intracranial pressure (ICP) monitor insertion or external ventricular drainage that can be used as ICP monitor.<br>* Other names: physiological monitoring;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neurological status | Glasgow coma scale/Mortality | Discharge out of the intensive care unit, averaged 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Wavelet transform, Deep learning
AIT-082 Phase 1B Study

Study Overview
=================
Brief Summary
-----------------
AIT-082 is a novel small molecule that crosses the blood-brain barrier to enhance nerve function by increasing levels of neurotrophic growth factors and encouraging nerve sprouting in the brain. Preclinical studies in animals have shown that AIT-082 improves memory in aged animals and in animals with neurological deficits. This study was a double-blind placebo-controlled safety study that was designed to study whether AIT-082 may delay age-related mental decline. Eight healthy older volunteers at two clinical sites were given single, weekly, rising doses of AIT-082 or placebo for 5 weeks; were tested for side effects and absorption; and underwent a battery of neuropsychological memory tests, including word and number recall tests.

Conditions
-----------------
Memory Disorders

Intervention / Treatment
-----------------
* Drug: AIT-082


Participation Criteria
=================
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: AIT-082|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Memory, Mild cognitive impairment, Nerve growth factors
Myocarditis Treatment Trial

Study Overview
=================
Brief Summary
-----------------
To determine whether immunosuppressive treatment improved cardiac function in patients with biopsy-proven myocarditis.

Detailed Description
-----------------
BACKGROUND: Heart failure due to myocarditis can be a devastating illness. At the same time, immunosuppressive therapy is associated with considerable risks of untoward side effects. Clinicians did not know whether, under what circumstances, or in what form, this hazardous treatment should be used in such critically ill patients. In addition, if immunosuppressive therapy was of benefit, then endomyocardial biopsy in patients suspected of having myocarditis was a justified procedure. The trial also provided information concerning the side effects of immuno-suppressive therapy in such patients. DESIGN NARRATIVE: Patients were randomized into two treatment arms consisting of conventional therapy alone for congestive heart failure or combined with a twenty-four week regimen of immunosuppressive therapy. Immunosuppressive therapy consisted of prednisone with either cyclosporine or azathioprine. The primary outcome measure was a change in the left ventricular ejection fraction at twenty-eight weeks. Secondary endpoints included survival, failures of therapy, requirements for conventional therapy, assessments of symptoms, myocardial histology, and arrhythmias. The study completion date listed in this record was obtained from the Query/View/Report (QVR) System.

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases, Myocarditis

Intervention / Treatment
-----------------
* Drug: cyclosporine
* Drug: prednisone


Participation Criteria
=================
Eligibility Criteria
-----------------
Men and women, 18 years of age or older, with left ventricular failure and biopsy-documented myocarditis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: cyclosporine|nan|
|Drug: prednisone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence

Study Overview
=================
Brief Summary
-----------------
A pre-market, prospective, non-randomized acute feasibility study for the treatment of patients with urinary incontinence (UI) as a consequence of urinary incontinence.

Official Title
-----------------
Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence

Conditions
-----------------
Overactive Bladder

Intervention / Treatment
-----------------
* Device: AHLeveeS System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject was eligible for treatment and indication for the Medtronic InterStim system or InterStim II Subject wished to undergo an InterStim or InterStim II implant procedure after this acute clinical investigation Subject was in good health in the opinion of the investigator Subject was able to understand and voluntarily signed and dated the Ethics Committee approved informed consent form prior to initiation of any screening or study-specific procedures Subject was minimum of 18 years and maximum of 65 years of age Exclusion Criteria: - Subject had any of the contraindications for the InterStim system or InterStim II system

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Device Feasibility
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Investigational SNS device<br> | Device: AHLeveeS System<br>* AHLeveeS System for treatment of overactive bladder<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sacral Nerve Response measured by observed bellow response and big toe flexion | Stimulation of the S3 sacral nerve measured by observed bellows response and big toe flexion | Procedure | 
| AHLeveeS System placement in the S3 foramen assessed by fluoroscopy image | Confirm that the AHLeveeS System can be correctly placed and inserted in close proximity of the sacral nerve in the S3 foramina assessed by fluoroscopy image | Procedure |
Treatment of Negative Symptoms and Schizophrenia

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the therapeutic efficacy of a neuromodulation technique, tDCS (transcranial direct current stimulation) used as a complementary treatment on negative symptoms. 60 patients will be randomized into two groups (active tDCS vs sham tDCS) and will be assessed after the intervention, 1 and 3 months after.Secondary outcomes shall include neuropsychological assessment, general symptomatology, extrapyramidal symptoms and social functioning.

Official Title
-----------------
A Double Blind Sham Controlled Trial of tDCS for Treatment of Negative Symptoms in Patients With Schizophrenia

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Device: transcranial direct current stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Schizophrenia with prominent negative symptoms Exclusion Criteria: other psychiatric or neurological diseases specific tDCS limitations

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: active tDCS<br>Transcranial Direct Current Stimulation : 10 sessions twice a day during 5 days, with a 2 mA intensity during 20 minutes. | Device: transcranial direct current stimulation<br> <br> |
| Sham Comparator: Sham tDCS<br>Transcranial Direct Current Stimulation : 10 sessions twice a day during 5 days, with a sham stimulation during 20 minutes. Initial stimulation followed by turning off the device as to ensure blinding. | Device: transcranial direct current stimulation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Scale for the Assessment of Negative Symptoms |  | up to 3 months after intervention |
Role of Diaphragm Fatigue in Weaning From Mechanical Ventilation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the diaphragm develops contractile fatigue during a weaning trial and if this is associated with weaning failure.

Official Title
-----------------
Pilot Study on the Role of Diaphragm Fatigue in Weaning From Mechanical Ventilation

Conditions
-----------------
Weaning, Respiratory Muscle Function

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 18 year mechanical ventilation for at least 3 days the treating physician judges the patient to be ready to be weaned from the ventilator informed consent Exclusion Criteria: pre-existent muscle disease (congenital or acquired) or diseases / disorders know to be associated with myopathy including auto-immune diseases. upper airway / esophageal pathology (i.e. recent surgery, esophageal varices, diaphragmatic hernia) recent (< 1 month) nasal bleeding phrenic nerve lesions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Weaning failure<br> | |
| Weaning succes<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fatiguability of the diaphragm |  | Multiple measurements within 24 hours after start of weaning trial |